Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
- 1 May 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (13), 1460-1466
- https://doi.org/10.1200/jco.2014.55.9898
Abstract
Purpose To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer. Patients and Methods Data from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox proportional hazards regression models were used for statistical analyses. Results In 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8 months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; P = .002). IP therapy improved survival of those with gross residual (≤ 1 cm) disease (AHR, 0.75; 95% CI, 0.62 to 0.92; P = .006). Risk of death decreased by 12% for each cycle of IP chemotherapy completed (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Factors associated with poorer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .001), gross residual versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; P < .001), and fewer versus more cycles of IP chemotherapy (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Younger patients were more likely to complete the IP regimen, with a 5% decrease in probability of completion with each year of age (odds ratio, 0.95; 95% CI, 0.93 to 0.96; P < .001). Conclusion The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.Keywords
This publication has 39 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free SurvivalJNCI Journal of the National Cancer Institute, 2009
- Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2008
- A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancerInternational Journal of Gynecologic Cancer, 2007
- Patterns and Progress in Ovarian Cancer Over 14 YearsObstetrics & Gynecology, 2006
- Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinomaGynecologic Oncology, 2006
- Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstetrics & Gynecology, 2003
- High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-upGynecologic Oncology, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the OtherThe Annals of Mathematical Statistics, 1947